ClinicalTrials.gg
RecruitingNCT06034002Updated Apr 17, 2026

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Phase 1 interventional study of INCA033989 and Ruxolitinib in Myeloproliferative Neoplasms, sponsored by Incyte Corporation. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
290
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies in Myeloproliferative Disorders by Incyte Corporation — 3 open to participants now, 7 under way, none of them phase 3. Myeloproliferative Disorders · Incyte Corporation.

Planned enrollment
2nd of 23
290 · median 97
Started
2023
with 1 other
Phase 1
6 of 25
3 open now
Registered
22nd of 25
by date

Among the 25 studies in Myeloproliferative Disorders by Incyte Corporation, this one is the 2nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 in phase 1, and was the 22nd registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

3 of the 25 studies in Myeloproliferative Disorders by Incyte Corporation are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Myeloproliferative Disorders by Incyte Corporation, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.

03

Conditions studied

  • Myeloproliferative Neoplasms

Keywords

  • Myeloproliferative Neoplasms
  • Myelofibrosis
  • Essential thrombocythemia
  • CALR mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 6 months.
  • Willingness to undergo a pretreatment and regular on-study BM and aspirates (as appropriate to disease).
  • Existing documentation from a qualified local laboratory of CALR exon-9 mutation.
  • Participants with MF or ET as defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Presence of any hematological other than ET, PMF, or post-ET MF.
  • Prior history of major bleeding, or thrombosis within the last 3 months prior to study enrollment.
  • Participants with laboratory values exceeding the protocol defined thresholds.
  • Has undergone any prior allogenic or stem-cell transplantation or such transplantation is planned.
  • Active invasive malignancy over the previous 2 years.
  • History of or uncontrolled cardiac disease.
  • Active or chronic or active or known history of .
  • Any prior chemotherapy, immunomodulatory drug therapy, therapy, biological therapy, endocrine therapy, targeted therapy, antibody, or hypomethylating agent used to treat the participant's disease, with the exception of ruxolitinib for TGBs only, within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
  • Participants undergoing treatment with G-CSF, GM-CSF, or TPO-R agonists at any time within 4 weeks before the first dose of study treatment.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
290 participants (estimated)

Study arms

  • Experimental
    Part 1a Dose Escalation Cohort Disease Group A - with MF

    INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myelofibrosis (MF) will enroll in this group.

    Drug: INCA033989

  • Experimental
    Part 1a Dose Escalation Cohort Disease Group A - with ET

    INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with essential thrombocythemia (ET) will enroll in this group.

    Drug: INCA033989

  • Experimental
    Part 1a: Dose Escalation Cohort Disease Group B - with TGB-MF SubOpt R

    INCA033989 will be administered at a protocol defined starting regimen in 28- day cycles and will allow for the evaluation of INCA033989 in combination with ruxolitinib to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myelofibrosis (MF) exhibiting suboptimal response (SubOpt R) will enroll in this group.

    Drug: INCA033989 · Drug: Ruxolitinib

  • Experimental
    Part 1b: Dose Expansion - with MF

    INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) myelofibrosis MF will enroll in this group.

    Drug: INCA033989

  • Experimental
    Part 1b: Dose Expansion - with TGB-MF SubOpt R

    INCA033989 will be administered as an add-on therapy in combination with ruxolitinibat at the RDE(s) identified during Part 1a. Participants with treatment Group B (TGB) MF SubOpt R will enroll in this group.

    Drug: INCA033989 · Drug: Ruxolitinib

  • Experimental
    Part 1b: Dose Expansion - with ET

    INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) essential thrombocythemia (ET) will enroll in this group.

    Drug: INCA033989

  • Experimental
    Part 1c: Dose Expansion

    INCA033989 will be administered at the dose level found to exhibit an overall positive benefit/risk as monotherapy or as combination therapy with Ruxolitinib. Participants with myelofibrosis (MF) will enroll in this group. The participants enrolled in the monotherapy arm will be offered the option to crossover to combination therapy with ruxolitinib if a suboptimal response to monotherapy is observed after 12 weeks.

    Drug: INCA033989 · Drug: Ruxolitinib

Interventions

  • INCA033989 will be administered at protocol defined dose.

  • Rux will be administered according to Prescribing Information/SmPC.

    Also known as: Jakafi

06

What researchers measure

Primary outcomes

  1. Number of participants with Dose Limiting Toxicities (DLTs)

    Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.

    Time frame: Up to 28 days

  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug, including those leading to dose modification or discontinuation.

    Time frame: Up to 3 years and 60 days

Secondary outcomes

  1. Participants with MF: Response using the revised IWG-MRT and ELN response criteria for MF

    Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria.

    Time frame: Up to 3 years and 60 days

  2. Participants With MF: Percentage of participants achieving spleen volume reduction as defined in the protocol

    Defined as percentage of participants with a protocol defined Spleen Volume Reduction.

    Time frame: Up to 24 weeks

  3. Participants with symptomatic anemia: Anemia Response as defined in the protocol

    Anemia Response as defined by the protocol.

    Time frame: Up to 24 weeks

  4. Participants with ET: Response using the revised IWG-MRT and ELN response criteria for ET

    Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria.

    Time frame: Up to 3 years and 60 days

  5. Incidence of AEs, ECGs, vital signs, and clinical laboratory evaluation

    To evaluate the safety of INCA033989.

    Time frame: Up to 3 years and 60 days

  6. Percentage of participants achieving ≥ 50% reduction from baseline in total symptom score (TSS)

    Defined as the percentage of participants achieving ≥ 50% reduction from baseline in TSS.

    Time frame: Week 12 and Week 24

  7. Mean change from baseline in TSS

    Mean change in TSS from baseline.

    Time frame: Week 12 and Week 24

  8. Mean change in disease-related allele burden

    Mean change from baseline in disease-related variant allele frequency quantified by targeted NGS and evaluated with myeloid and lymphoid proportion in blood.

    Time frame: Up to 3 years and 60 days

  9. Pharmacokinetics Parameter: Cmax of INCA033989 alone or for the combination of INCA033989 with ruxolitinib

    Defined as maximum observed plasma concentration of INCA033989 alone or for the combination of INCA033989 with ruxolitinib.

    Time frame: Up to 3 years and 60 days

  10. Pharmacokinetics Parameter: Tmax of INCA033989 alone or for the combination of INCA033989 with ruxolitinib

    Defined as the time to reach the maximum plasma concentration of INCA033989 alone or for the combination of INCA033989 with ruxolitinib.

    Time frame: Up to 3 years and 60 days

  11. Pharmacokinetics Parameter: Cmin of INCA033989 alone or for the combination of INCA033989 with ruxolitinib

    Defined as the minimum observed plasma concentration of INCA033989 alone or for the combination of INCA033989 with ruxolitinib.

    Time frame: Up to 3 years and 60 days

  12. Pharmacokinetics Parameter: AUC(0-t) of INCA033989 alone or for the combination of INCA033989 with ruxolitinib

    Defined as the area under the concentration-time curve up to the last measurable concentration of INCA033989 alone or for the combination of INCA033989 with ruxolitinib.

    Time frame: Up to 3 years and 60 days

  13. Pharmacokinetics Parameter: AUC 0-∞ of INCA033989 alone or for the combination of INCA033989 with ruxolitinib

    Defined as the area under the concentration-time curve from 0 to infinity of INCA033989 alone or for the combination of INCA033989 with ruxolitinib.

    Time frame: Up to 3 years and 60 days

  14. Pharmacokinetics Parameter: CL/F of INCA033989 alone or for the combination of INCA033989 with ruxolitinib

    Defined as the apparent oral dose clearance of INCA033989 alone or for the combination of INCA033989 with ruxolitinib.

    Time frame: Up to 3 years and 60 days

  15. Pharmacokinetics Parameter: Vz/F of INCA033989 alone or for the combination of INCA033989 with ruxolitinib

    Defined as the apparent oral dose volume of distribution of INCA033989 alone or for the combination of INCA033989 with ruxolitinib.

    Time frame: Up to 3 years and 60 days

  16. Pharmacokinetics Parameter: t1/2 of INCA033989 alone or for the combination of INCA033989 with ruxolitinib

    Defined as the apparent terminal phase disposition half-life of INCA033989 alone or for the combination of INCA033989 with ruxolitinib.

    Time frame: Up to 3 years and 60 days

07

Study locations

13 of 13 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Oct 2028, 58 months after the start.

Of 40 phase 1 interventional studies under Myeloproliferative Disorders, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 140. This study's planned 58 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Sep 13, 2023
StartActual
Dec 4, 2023
Primary completionEst.
Oct 29, 2028
CompletionEst.
Oct 29, 2028
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06034002
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Dec 4, 2023
Primary completion
Oct 29, 2028 (estimated)
Completion
Oct 29, 2028 (estimated)
Last update
Apr 17, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-mutant Calreticulin Monoclonal Antibody INCA033989

Start the discussion